pre-IPO PHARMA

COMPANY OVERVIEW

Aulos Bioscience, an ATP company, is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics. Aulos is initially developing unique IL-2 targeting antibodies that it believes have the potential to become best-in-class treatments for solid tumors.


LOCATION

  • Larkspur, CA, USA

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://aulosbio.com/


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    apple-tree-partners


    PRESS RELEASES


    Nov 10, 2022

    Aulos Bioscience Presents Initial Data From First-in-Human Phase 1/2 Clinical Trial of Computationally Designed Antibody AU-007 at 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting


    Oct 5, 2021

    Aulos Bioscience to Present New Preclinical Data on Computationally Evolved IL-2 Human Antibody AU-007 at 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting


    Jun 14, 2021

    Jim Vasselli, M.D., Joins Aulos Bioscience as Chief Medical Officer


    May 17, 2021

    Aulos Bioscience Appoints Leo Redmond as Chief Financial Officer


    Mar 30, 2021

    Mace Rothenberg, M.D., Joins Aulos Bioscience Board of Directors USA - English USA - English USA - English


    For More Press Releases


    Google Analytics Alternative